First report of a very rare complication in a case of nonsmall cell lung carcinoma

While immune checkpoint inhibitors like pembrolizumab are promising agents for nonsmall cell lung carcinoma treatment, increased use is leading to increased immune-related adverse events, including endocrinopathies such as adrenal insufficiency. https://bit.ly/3iMfhUk

Detalles Bibliográficos
Autores principales: Moreira, Inês, Vilariça, Ana Sofia, Alves, Paula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Expert Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753643/
https://www.ncbi.nlm.nih.gov/pubmed/35035567
http://dx.doi.org/10.1183/20734735.0107-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753643/
https://www.ncbi.nlm.nih.gov/pubmed/35035567
http://dx.doi.org/10.1183/20734735.0107-2021

Ejemplares similares